^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)

i
Other names: NR4A2, Nuclear Receptor Subfamily 4 Group A Member 2, TINUR, NOT, HZF-3, NURR1, RNR1, Transcriptionally-Inducible Nuclear Receptor, Immediate-Early Response Protein NOT, Orphan Nuclear Receptor NURR1, Transcriptionally Inducible Nuclear Receptor Related 1, NGFI-B/Nur77 Beta-Type Transcription Factor Homolog, Nuclear Receptor Subfamily 4, Group A, Member 2, Nur Related Protein-1, Human Homolog Of, Intermediate-Early Receptor Protein, Orphan Nuclear Receptor NR4A2, T-Cell Nuclear Receptor NOT, Nuclear Receptor Related 1
Associations
Trials
3d
Cytokine armored CAR T cells for cancer immunotherapy. (PubMed, Immunol Cell Biol)
Reprogramming of the tumor microenvironment and recruitment of host antitumor immunity through (c) IL-36γ10 or (d) IL-1211,12 engineering. (e) Tumor-inducible cytokine expression utilizing synthetic NFAT or endogenous NR4A2 promoter systems to restrict systemic expression of potent cytokines for improved safety.
Journal • IO biomarker
|
NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
6d
Janus kinase 2 regulates Nurr1 protein stability in dopaminergic neurons of the aging midbrain. (PubMed, bioRxiv)
Together, these findings reveal a phosphorylation-independent mechanism by which JAK2 stabilizes Nurr1 protein and enhances its transcriptional activity. Our results further suggest that age-associated induction of JAK2 in dopaminergic neurons may promote neuronal resilience by maintaining Nurr1 protein stability during aging.
Journal
|
JAK2 (Janus kinase 2) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
1m
A series of extraskeletal myxoid chondrosarcomas with rare morphological and molecular variations. (PubMed, Histopathology)
These five cases of EMC highlight the continuous morphological spectrum of this tumour, demonstrating significantly greater histological diversity than classically described. The identification of novel fusion partners further expands its genetic landscape.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • EWSR1 (EWS RNA Binding Protein 1) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • FUS (FUS RNA Binding Protein) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
2ms
Integrative bioinformatics and machine learning approaches identify novel diagnostic signatures for oxaliplatin-resistant colorectal cancer. (PubMed, Int J Colorectal Dis)
Our study establishes a novel multi-gene diagnostic signature for oxaliplatin resistance through integrative bioinformatics and machine learning approaches. The comprehensive molecular characterization and identification of potential therapeutic candidates provide new insights into resistance mechanisms and clinical management strategies for oxaliplatin-resistant colorectal cancer.
Journal
|
CD8 (cluster of differentiation 8) • CAV2 (Caveolin 2) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
|
oxaliplatin
2ms
NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXCL5/CXCR2 signaling axis. (PubMed, Cancer Lett)
Further treatment with CXCL5 ligand significantly induced neuritogenesis, while the neurite outgrowth was abrogated when cotreated with CXCR2 (receptor for CXCL5) inhibitor SCH527123...NR4A2 knockdown in UMSCC1 cells impaired tumor formation in vivo, and the xenograft tissues exhibited significant downregulation of CXCL5, providing direct in vivo evidence for the NR4A2-CXCL5 axis in tumor progression. NR4A2 is a key driver of CXCL5-mediated PNI and the NR4A2/CXCL5/CXCR2 signaling axis is a potential therapeutic target in HNSCC and PDAC.
Journal
|
RAC1 (Rac Family Small GTPase 1) • CCL2 (Chemokine (C-C motif) ligand 2) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
|
navarixin (MK-7123)
3ms
Intratumoral Lactobacillus johnsonii Enhances Sensitivity to PD-1 Blockade by Inducing CD8+ T Cell Expansion in Hepatocellular Carcinoma. (PubMed, Cancer Res)
Crucially, the anti-tumor efficacy of L. johnsonii was CD8+ T cell-dependent, as depletion abolished its activity. This work unveils a mechanism by which L. johnsonii and its metabolite NA enrich intratumoral IFN-γ+PD-1+CD8+ T cells, thereby reshaping the immune microenvironment to potentiate immunotherapy efficacy and suppress HCC recurrence.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • GZMB (Granzyme B) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
4ms
Prolonged Loss of Oxidative Phosphorylation and Mitochondrial Mass Characterize CD66b + Leukocytes from Patients with Sepsis. (PubMed, bioRxiv)
We have also identified gene silencing, reduced gene expression of key transcription factors that regulate mitochondrial biogenesis, as well as increased long non-coding RNA as potential drivers of this unique metabolic phenotype. These results highlight the potential benefit of targeting metabolism in sepsis to promote immune homeostasis and recovery.
Journal
|
NR4A3 (Nuclear receptor subfamily 4 group A member 3) • NR4A1 (Nuclear Receptor Subfamily 4 Group A Member 1) • CEACAM8 (CEA Cell Adhesion Molecule 8) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
4ms
Single-cell multi-omic landscape reveals anatomical-specific immune features in adult and pediatric sepsis. (PubMed, Nat Immunol)
Plasma proteomics revealed shared mediators including interleukin-6 and EN-RAGE across anatomical sites and ages. Together, our findings delineate anatomical-specific and age-specific immune programs in sepsis, highlighting candidate targets for precision immunotherapy.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CCL4 (Chemokine (C-C motif) ligand 4) • CD14 (CD14 Molecule) • CCL3 (C-C Motif Chemokine Ligand 3) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
4ms
Novel HSPA8-NR4A2 rearrangement in extraskeletal myxoid chondrosarcoma: a sarcoma mimicker of neuroendocrine neoplasia. (PubMed, Virchows Arch)
Transcriptome cluster comparative analysis placed its expression profile close to pancreas neuroendocrine tumors. This case suggests NR4A2 as a functionally substitute for NR4A3 in tumorigenesis and a neuroendocrine lineage differentiation for a subset of EMC.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8)
|
TMB-L
5ms
HPV integration in head and neck cancer: downstream splicing events and expression ratios linked with poor outcomes. (PubMed, Clin Cancer Res)
By focusing on RNA instead of DNA, we expand our understanding of the carcinogenic mechanisms of HPVint, in part addressing the conflicting findings of whether HPVint is associated with aggressive phenotypes and worse clinical consequences and provide potential biomarkers to advance precision oncology in HPV-associated HNSCC. Newly identified genes with recurrent integration events may serve as candidates for targeted therapy.
Journal
|
PD-L1 (Programmed death ligand 1) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
5ms
Lithium for Parkinson's: an Extension Trial (clinicaltrials.gov)
P1/2, N=35, Enrolling by invitation, State University of New York at Buffalo | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: Feb 2026 --> Jun 2026
Trial completion date • Trial primary completion date
|
NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)
5ms
Evaluating SH-SY5Y cells as a dopaminergic neuronal model: morphological, transcriptomic, and proteomic insights. (PubMed, Turk J Biol)
While SH-SY5Y cells exhibited dopaminergic characteristics following the blended differentiation protocol, the transient expression of key neuronal markers and the need for continuous external stimuli raised concerns about the stability and functional maturity of these differentiated cells as an in vitro PD model. These findings suggest that SH-SY5Y cells might not fully capture the properties of mature neurons.
Journal
|
NES (Nestin) • BDNF (Brain Derived Neurotrophic Factor) • NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2)